Search Results - "de Giorgi, U."

Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy by Conteduca, V., Medri, M., Mazzoni, L., De Giorgi, U., Stanganelli, I.

“…Lichenoid reactions are one of the most frequently observed toxicities with anticancer agents and, recently, a rapid emergence of immunotherapies in oncology…”
Get full text

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide by Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.

“…Background Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients…”
Get full text

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer by Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., Mardiak, J.

“…Summary Background Germ cell tumors (GCTs) are highly curable diseases; however, not all patients can be cured. Patients in their second relapse have…”
Get full text

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer by Cursano, M. C., Conteduca, V., Scarpi, E., Gurioli, G., Casadei, C., Gargiulo, S., Altavilla, A., Lolli, C., Vincenzi, B., Tonini, G., Santini, D., De Giorgi, U.

“…In localized prostate cancer (PCa), Grade Group (GG) and Gleason Score (GS) have a well-established prognostic role. In metastatic castration resistant…”
Get full text

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy by Lorch, Anja, Beyer, Jörg, Bascoul-Mollevi, Caroline, Kramar, Andrew, Einhorn, Lawrence H, Necchi, Andrea, Massard, Christophe, De Giorgi, Ugo, Fléchon, Aude, Margolin, Kim A, Lotz, Jean-Pierre, Germa Lluch, Jose Ramon, Powles, Thomas, Kollmannsberger, Christian K

“…To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Data from…”
Get full text

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer by Oldenburg, J., Aparicio, J., Beyer, J., Cohn-Cedermark, G., Cullen, M., Gilligan, T., De Giorgi, U., De Santis, M., de Wit, R., Fosså, S.D., Germà-Lluch, J.R., Gillessen, S., Haugnes, H.S., Honecker, F., Horwich, A., Lorch, A., Ondruš, D., Rosti, G., Stephenson, A.J., Tandstad, T.

“…Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%–75% have clinical stage I (CSI) disease. Both…”
Get full text

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up by Oldenburg, J., Berney, D.M., Bokemeyer, C., Climent, M.A., Daugaard, G., Gietema, J.A., De Giorgi, U., Haugnes, H.S., Huddart, R.A., Leão, R., Sohaib, A., Gillessen, S., Powles, T.

“…•This ESMO Clinical Practice Guideline provides key recommendations on the management of testicular seminoma and non-seminoma.•Authorship includes a…”
Get full text

Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing? by De Giorgi, U., Giunta, E.F., Verzoni, E., Procopio, G.

Get full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial by Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, Abadie-Lacourtoisie, Sophie, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bentzen, Anne Gry, Berton, Dominique, Bjørge, Line, Bjurberg, Maria, Bologna, Alessandra, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Nagao, Shoji, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tewari, Krishnansu, Todo, Yukiharu, Wimberger, Pauline, Woelber, Linn, You, Benoît, Yunokawa, Mayu

“…The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial…”
Get full text

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study by Conteduca, V., Wetterskog, D., Sharabiani, M.T.A., Grande, E., Fernandez-Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M.J., Climent, M.A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M.I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.

“…There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify…”
Get full text

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone by Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U

“…Background: This study aimed to investigate copy number variations (CNVs) of CYP17A1 and androgen receptor ( AR ) genes in serum cell-free DNA collected before…”
Get full text

Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review by Cursano, M.C., Iuliani, M., Casadei, C., Stellato, M., Tonini, G., Paganelli, G., Santini, D., De Giorgi, U.

“…•In bone mCRPC, each treatment has an effect on PCa cells and bone microenvironment.•Clinical trials have been performed to evaluate radium 223-based…”
Get full text

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond by Sirico, M., Jacobs, F., Molinelli, C., Nader-Marta, Guilherme, Debien, V., Dewhurst, H. Faith, Palleschi, M., Merloni, F., Gianni, C., De Giorgi, U., de Azambuja, Evandro

“…The results of the SOLAR-1 and CAPItello-291, highlight the benefit of the ɑ-selective phosphoinositide 3-Kinase Pathway inhibitor (PI3Ki) alpelisib and the…”
Get full text

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) by Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.-N., Kumar Pal, S., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Necchi, A., Sternberg, C.N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Bellmunt, J., Galsky, M.D.

“…Cisplatin-based combination chemotherapy is the standard treatment of advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin…”
Get full text

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 by PEDRAZZOLI, P, FERRANTE, P, KULEKCI, A, SCHIAVO, R, DE GIORGI, U, CARMINATI, O, MARANGOLO, M, DEMIRER, T, SIENA, S, ROSTI, G

“…The aim of this study was to identify trends in high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (ASCT) and to assess…”
Get full text

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy by Pignata, S, Califano, D, Lorusso, D, Arenare, L, Bartoletti, M, De Giorgi, U, Andreetta, C, Pisano, C, Scambia, G, Lombardi, D, Farolfi, A, Cinieri, S, Passarelli, A, Salutari, V, De Angelis, C, Mignogna, C, Priolo, D, Capoluongo, E D, Tamberi, S, Scaglione, G L, Arcangeli, V, De Cecio, R, Scognamiglio, G, Greco, F, Spina, A, Turinetto, M, Russo, D, Carbone, V, Casartelli, C, Schettino, C, Perrone, F

“…Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced…”
Get more information

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma by Santoni, M, De Giorgi, U, Iacovelli, R, Conti, A, Burattini, L, Rossi, L, Luca Burgio, S, Berardi, R, Muzzonigro, G, Cortesi, E, Amadori, D, Cascinu, S

“…Background: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess…”
Get full text

Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study by Bergamini, A., Cormio, G., Ferrandina, G., Lorusso, D., Giorda, G., Scarfone, G., Bocciolone, L., Raspagliesi, F., Tateo, S., Cassani, C., Savarese, A., Breda, E., De Giorgi, U., Mascilini, F., Candiani, M., Kardhashi, A., Biglia, N., Perrone, A.M., Pignata, S., Mangili, G.

“…About 30% of Adult type granulosa cell tumors of the ovary (AGCTs) are diagnosed in fertile age. In stage I, conservative surgery (fertility-sparing surgery,…”
Get full text

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy by Banna, G. L., Di Quattro, R., Malatino, L., Fornarini, G., Addeo, A., Maruzzo, M., Urzia, V., Rundo, F., Lipari, H., De Giorgi, U., Basso, U.

“…Purpose To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs). Methods/Patients We explored…”
Get full text

Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients by Celli, M, De Giorgi, U, Caroli, P, Di Iorio, V, Fantini, L, Rossetti, V, Foca, F, Nicolini, S, Giganti, M, Paganelli, G, Matteucci, F

“…Purpose To evaluate the clinical value of 68 Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer (BCR). Methods One hundred three…”
Get full text